GATA2 has been reported to directly upregulate IGF2 in chemo-resistant prostate cancer [51], while IGF2 activity leads to PAX2 overexpression in Wilms’ tumor [13], suggesting a possible signalling axis in NET-PATZ1. This evidence concerns the gene PATZ1 and prostate cancer.